GT201700245A - Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina - Google Patents
Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketaminaInfo
- Publication number
- GT201700245A GT201700245A GT201700245A GT201700245A GT201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A GT 201700245 A GT201700245 A GT 201700245A
- Authority
- GT
- Guatemala
- Prior art keywords
- ketamine
- csa
- salt
- processes
- preparation
- Prior art date
Links
- 229960003299 ketamine Drugs 0.000 title abstract 8
- 150000003839 salts Chemical class 0.000 title abstract 4
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 abstract 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract 1
- 229960000450 esketamine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000004682 monohydrates Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/23—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A PROCESOS PARA LA PREPARACIÓN DE ESKETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS A PROCESOS PARA LA RESOLUCIÓN DE S-KETAMINA A PARTIR DE UNA MEZCLA RACÉMICA O ENANTIOMÉRICAMENTE ENRIQUECIDA DE KETAMINA. LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA, ADEMÁS, A UNA SAL DE (S)-CSA DE S-KETAMINA, MÁS PARTICULARMENTE, UNA FORMA MONOHIDRATO DE LA SAL DE (S)-CSA DE S-KETAMINA; Y A UNA SAL DE (R)-CSA DE R-KETAMINA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562160659P | 2015-05-13 | 2015-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201700245A true GT201700245A (es) | 2019-08-07 |
Family
ID=56068863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201700245A GT201700245A (es) | 2015-05-13 | 2017-11-13 | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina |
Country Status (25)
Country | Link |
---|---|
US (3) | US20160332962A1 (es) |
EP (1) | EP3294704B1 (es) |
JP (1) | JP6882990B2 (es) |
KR (1) | KR102610047B1 (es) |
CN (1) | CN107750245B (es) |
AU (1) | AU2016260911B2 (es) |
BR (1) | BR112017024243B1 (es) |
CA (1) | CA2985696A1 (es) |
CL (3) | CL2017002854A1 (es) |
CO (1) | CO2017011553A2 (es) |
CR (1) | CR20170517A (es) |
EA (1) | EA201792503A1 (es) |
EC (1) | ECSP17075386A (es) |
ES (1) | ES2767708T3 (es) |
GT (1) | GT201700245A (es) |
HK (1) | HK1251546A1 (es) |
IL (1) | IL255433B2 (es) |
MX (1) | MX2017014473A (es) |
MY (1) | MY181938A (es) |
PE (1) | PE20180527A1 (es) |
PH (1) | PH12017502024A1 (es) |
SA (1) | SA517390322B1 (es) |
UA (1) | UA121049C2 (es) |
WO (1) | WO2016180984A1 (es) |
ZA (1) | ZA201708417B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
MX2017001908A (es) | 2014-08-13 | 2017-08-08 | Janssen Pharmaceutica Nv | Metodo para el tratamiento de la depresion. |
CA2961208A1 (en) | 2014-09-15 | 2016-03-24 | Janssen Pharmaceutica Nv | Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
CN117531017A (zh) | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
ES2907692T3 (es) * | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
BR112020016500A2 (pt) | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea |
CN110218157B (zh) * | 2018-03-01 | 2022-08-23 | 江苏恒瑞医药股份有限公司 | 一种r-氯胺酮及其可药用盐的制备方法 |
AU2019262197A1 (en) | 2018-05-04 | 2020-11-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
KR20210028159A (ko) * | 2018-06-27 | 2021-03-11 | 클렉시오 바이오사이언시스 리미티드 | 주요 우울 장애를 치료하는 방법 |
CN108659004B (zh) * | 2018-07-12 | 2020-11-10 | 福安药业集团重庆博圣制药有限公司 | 奥拉西坦异构体的制备方法 |
AU2019352028A1 (en) | 2018-10-05 | 2021-03-11 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
MA55218A (fr) | 2019-03-05 | 2022-01-12 | Janssen Pharmaceuticals Inc | Eskétamine pour le traitement de la dépression |
US20220220062A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Synthetic methods of preparing esketamine |
CN112375005A (zh) * | 2019-08-16 | 2021-02-19 | 国药集团工业有限公司 | 一种氯胺酮、其衍生物或其盐的消旋化方法 |
EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
WO2022208144A1 (en) * | 2021-03-31 | 2022-10-06 | Supriya Lifescience Ltd | A crystalline form of 2-(2-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride and method thereof |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH535201A (de) * | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
JPS5857420B2 (ja) * | 1975-02-12 | 1983-12-20 | ワコウジユンヤクコウギヨウ カブシキガイシヤ | Dl− フエニルグリシンノ コウガクブンカツホウホウ |
JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
JPS6314771A (ja) * | 1986-07-08 | 1988-01-21 | Sankyo Co Ltd | 光学活性イミダゾ−ル誘導体およびその製法 |
JPS63192753A (ja) * | 1987-02-05 | 1988-08-10 | Otsuka Pharmaceut Co Ltd | テトラヒドロキノリン誘導体の光学分割法 |
DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
JPH10507192A (ja) | 1994-10-17 | 1998-07-14 | アクゾ ノーベル ナムローゼ フェンノートシャップ | ラセミ混合物から鏡像異性体を分離する方法 |
PE8798A1 (es) | 1995-07-17 | 1998-03-02 | Pfizer | Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil] |
DE19619665C2 (de) * | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
TW430660B (en) * | 1996-05-30 | 2001-04-21 | Mochida Pharm Co Ltd | Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them |
EP1113785B1 (en) | 1998-07-24 | 2005-04-13 | Seo Hong Yoo | Clear aqueous solutions of bile acids |
US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
BRPI0002693B8 (pt) * | 2000-06-19 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | processo de obtenção dos enantiômeros da cetamina e seus sais farmaceuticamente aceitáveis |
US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
EP2012762A4 (en) | 2006-03-22 | 2010-03-10 | Sinai School Medicine | INTRANASAL ADMINISTRATION OF KETAMINE FOR THE TREATMENT OF DEPRESSION |
WO2007122130A1 (en) * | 2006-04-21 | 2007-11-01 | Zach System S.P.A. | Process for preparing dorzolamide |
EP2029136A4 (en) | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
DE102007009888A1 (de) | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
US8710070B2 (en) * | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
DK2582366T3 (en) | 2010-06-15 | 2015-12-07 | Gruenenthal Gmbh | A pharmaceutical combination for the treatment of pain. |
MX354547B (es) | 2011-11-14 | 2018-03-09 | Alfasigma Spa | Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión. |
US9012486B2 (en) * | 2011-11-14 | 2015-04-21 | Alex Chervinsky | Topical composition for pain relief |
PE20141906A1 (es) | 2012-03-12 | 2014-12-05 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento |
US20140057988A1 (en) | 2012-08-23 | 2014-02-27 | Stuart WEG | Anxiolytic composition, formulation and method of use |
AU2013328280B2 (en) | 2012-10-08 | 2017-12-21 | Auckland Uniservices Limited | Ketamine derivatives |
EP4309735A3 (en) | 2013-03-15 | 2024-04-17 | JANSSEN Pharmaceutica NV | Pharmaceutical composition of s-ketamine hydrochloride |
PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
JP6462663B2 (ja) | 2013-04-12 | 2019-01-30 | アイカーン スクール オブ メディシン アット マウント シナイ | 心的外傷後ストレス障害を処置するための方法 |
DK3043785T3 (da) * | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2016
- 2016-05-12 US US15/152,705 patent/US20160332962A1/en not_active Abandoned
- 2016-05-13 ES ES16724354T patent/ES2767708T3/es active Active
- 2016-05-13 CR CR20170517A patent/CR20170517A/es unknown
- 2016-05-13 MX MX2017014473A patent/MX2017014473A/es active IP Right Grant
- 2016-05-13 EP EP16724354.2A patent/EP3294704B1/en active Active
- 2016-05-13 MY MYPI2017704244A patent/MY181938A/en unknown
- 2016-05-13 BR BR112017024243-5A patent/BR112017024243B1/pt active IP Right Grant
- 2016-05-13 CA CA2985696A patent/CA2985696A1/en active Pending
- 2016-05-13 JP JP2017558956A patent/JP6882990B2/ja active Active
- 2016-05-13 AU AU2016260911A patent/AU2016260911B2/en active Active
- 2016-05-13 CN CN201680027740.1A patent/CN107750245B/zh active Active
- 2016-05-13 KR KR1020177035694A patent/KR102610047B1/ko active IP Right Grant
- 2016-05-13 EA EA201792503A patent/EA201792503A1/ru unknown
- 2016-05-13 UA UAA201712292A patent/UA121049C2/uk unknown
- 2016-05-13 PE PE2017002412A patent/PE20180527A1/es unknown
- 2016-05-13 WO PCT/EP2016/060922 patent/WO2016180984A1/en active Application Filing
-
2017
- 2017-11-05 IL IL255433A patent/IL255433B2/en unknown
- 2017-11-07 PH PH12017502024A patent/PH12017502024A1/en unknown
- 2017-11-10 CL CL2017002854A patent/CL2017002854A1/es unknown
- 2017-11-10 CO CONC2017/0011553A patent/CO2017011553A2/es unknown
- 2017-11-12 SA SA517390322A patent/SA517390322B1/ar unknown
- 2017-11-13 EC ECIEPI201775386A patent/ECSP17075386A/es unknown
- 2017-11-13 GT GT201700245A patent/GT201700245A/es unknown
- 2017-12-12 ZA ZA2017/08417A patent/ZA201708417B/en unknown
-
2018
- 2018-06-04 US US15/997,267 patent/US10815196B2/en active Active
- 2018-08-31 HK HK18111186.1A patent/HK1251546A1/zh unknown
-
2019
- 2019-04-18 CL CL2019001066A patent/CL2019001066A1/es unknown
-
2020
- 2020-07-13 CL CL2020001852A patent/CL2020001852A1/es unknown
- 2020-10-08 US US17/066,127 patent/US20210024461A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700245A (es) | Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina | |
EA201791420A1 (ru) | Соединения триазолопиримидина и их применения | |
TWD181857S (zh) | 香水瓶 | |
CO2017001884A2 (es) | Polimorfos de selinexor | |
EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
EA201692105A1 (ru) | Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1 | |
CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
MX2017008136A (es) | Sal de l-tartrato de pridopidina. | |
BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
BR112015028853A2 (pt) | Composição detergente com ph baixo | |
DOP2016000253A (es) | Nuevos compuestos | |
BR112017000135B8 (pt) | Processo para a preparação de ácidos 4-alcóxi-3-hidroxipicolínico | |
GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
EA201591678A1 (ru) | Антиперспирантные композиции | |
AR100365A1 (es) | Composición acuosa que comprende ibuprofeno y paracetamol en combinación, proceso para fabricarla y dispositivo inyector para administrarla | |
DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
EA201791645A1 (ru) | Новые соли и полиморфы scy-078 | |
CL2018002149A1 (es) | Proceso. | |
DE102016003950A8 (de) | Maschinenstrang zur Herstellung von Salpetersäure | |
BR112016023767A2 (pt) | forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações | |
BR112015028751A2 (pt) | processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas | |
MX2017003498A (es) | Sal de ester metilico de fenilglicina. | |
MX2017004770A (es) | Formas solidas del clorhidrato de nilotinib. | |
BR112017016626A2 (pt) | micro-organismo com capacidade para produzir ácido quinólico e método para produzir ácido quinólico com o uso do micro-organismo |